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hyperproduction of the chromosomal
enzymes, as well as resistant strains
without synergy, were disregarded.
During the first period, 15 (2.1%) of
707 outpatients were carriers of
Escherichia coli (14 patients) or
Proteus mirabilis (1 patient) with
ESBL. This percentage increased dur-
ing the second period, when 17
(3.8%) of 454 outpatients were carri-
ers of E. coli with ESBL, and again in
the third period, when 12 (7.5%) of
160 were carriers of E. coli (11
patients) or Enterobacter cloacae (1
patient) with ESBL. Characterization
of the different ESBL isolated during
the three study periods is in process.
Although Klebsiella pneumoniae car-
rying ESBL has been detected in our
hospital (7), as well as in other hospi-
tals in Barcelona (8), no ESBL-pro-
ducing K. pneumoniae strains were
identified in this survey.
Although we did not disregard
either the patients’ previous treatment
with antibiotics or previous hospital-
ization, these patients came to the
hospital from the community carrying
strains that express ESBL. Moreover,
during these three periods we
observed a significant increase in the
frequency of ESBL carriers (from
2.1% to 7.5%; p<0.005). These data
suggest that the community could be a
reservoir for these enzymes, as occurs
with other microorganisms (9–11).
Many questions remain unanswered
regarding the diffusion mechanisms
of this resistance in the community.
Confirmation of community-based
transmission of ESBL would indicate
a need for heightened vigilance and
further studies to determine the reser-
voirs and vehicles for dissemination
of ESBL within the community.
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Polymyxin-
Resistant
Acinetobacter spp.
Isolates: What Is
Next?
To the Editor: In Brazilian hospi-
tals, Acinetobacter spp. has been an
important etiologic agent of nosoco-
mial infections, mainly pneumonia
(1–3). In general, ampicillin/sulbac-
tam and carbapenems remain the last
therapeutic options for treatment of
such infections (3,4). However, resist-
ance rates to carbapenems have
increased, reaching rates approxi-
mately 12% or higher in some
Brazilian hospitals (1,3,4). Thus,
more toxic agents such as polymyxins
have been used as alternative thera-
peutic drugs against multidrug-resist-
ant Acinetobacter infections (5,6).
The clinical use of polymyxins has
been based on antimicrobial suscepti-
bility results and previous clinical
experience. However, the National
Committee for Clinical Laboratory
Standards (NCCLS) documents do
not currently provide interpretative
criteria for the testing of polymyxins
(7). In addition, the disk diffusion
technique was reported to be an unre-
liable method for evaluating the sus-
ceptibility to polymyxins (8). Since
Acinetobacter clinical specimens
exhibiting high MICs for polymyxins
(MIC, 8–32 µg/mL) were recently
detected, we searched for the frequen-
cy of occurrence of Acinetobacter
spp. strains exhibiting reduced sus-
ceptibility to polymyxin B among 100
bloodstream isolates of Acinetobacter
spp. (8). The bacterial isolates were
consecutively collected between
September 1999 and December 2000
from a tertiary Brazilian hospital,
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where Acinetobacter spp. infections
have reached endemic levels and
polymyxins have been frequently
used. Only one isolate per patient was
included in the study. 
The isolates were identified to the
species level using the BBL Crystal
System (Becton Dickinson, Sparks,
MD). The susceptibility to polymyxin
B and meropenem were tested by disk
diffusion and agar dilution techniques
according to NCCLS recommenda-
tions (9,10). The susceptibility inter-
pretative criteria for meropenem and
polymyxin B were based on the cur-
rent and former NCCLS documents,
respectively (7,11). The MIC was
defined as the lowest antimicrobial
concentration that inhibited bacterial
growth. Pseudomonas aeruginosa
ATCC 27853, Staphylococcus aureus
ATCC 25923, and Escherichia coli
ATCC 25922 were used as quality
control strains. Testing errors and
agreements were determined by com-
paring the results of the disk diffusion
with the standard criterion agar dilu-
tion method. Categorical agreement
was obtained when the isolates were
classified within the same susceptibil-
ity category. The very major and
major errors were related to false sus-
ceptibility and false resistance results,
respectively. To evaluate whether the
polymyxin B-resistant strains isolates
were epidemiologically related, these
isolates were molecularly typed by
pulsed-field gel electrophoresis
(PFGE) as previously described (12).
PFGE patterns were considered iden-
tical if they shared every band, similar
if they differed from one to three
bands, and distinct if they differed by
four or more bands (12). 
Despite the limitation of commer-
cial systems for identifying the genus
Acinetobacter at species level,
Acinetobacter baumannii (80.0%)
was the most commonly identified
species, followed by A. lwoffi (4.0%).
Sixteen percent of the Acinetobacter
isolates were not identified to species
level by the BBL Crystal System.
Meropenem (MIC50, 1 µg/mL) and
polymyxin B (MIC50, 1 µg/mL)
showed similar in vitro potency.
However, meropenem exhibited the
highest susceptibility rate (99.0% sus-
ceptible). In contrast to previous stud-
ies, only one strain was resistant to
meropenem (1,2,3,8), which indicates
that the carbapenem-susceptibility
rates among Acinetobacter spp. iso-
lates may vary according to the period
evaluated even in the same institution.
By using the polymyxin B resistance
breakpoint (MIC >4 µg/mL) present-
ed by the former NCCLS document,
which was recently validated, we
found that five Acinetobacter spp. iso-
lates were considered resistant to
polymyxin B (MICs, 8–32 µg/mL)
(8,11). All isolates were susceptible to
meropenem and belonged to A. bau-
mannnii (4) and A. lwoffi (1) species.
The polymyxin B–resistant isolates
were categorized as susceptible by
disk diffusion (100%, very major
error). The disk diffusion method is
widely used in Brazil and worldwide.
However, disk diffusion was con-
firmed to be an unreliable test for
detecting Acinetobacter spp. isolates
with reduced susceptibility to
polymyxins. These results are in
agreement with those previously
reported (8). 
Among the five polymyxin
B–resistant Acinetobacter spp., four
distinct patterns were characterized
by PFGE. Two polymyxin B–resistant
strains, which were isolated from dif-
ferent units of the São Paulo Hospital
complex, shared an identical PFGE
pattern. The PFGE results suggest that
the polymyxin B use may have played
a role in the selection of resistant
strains. On the other hand, two iso-
lates shared an identical PFGE pat-
tern, which raises the possibility of
patient-to-patient transmission of epi-
demic strains. Intra- and interhospital
dissemination of multidrug-resistant
Acinetobacter spp. clones has already
been reported in Brazilian hospitals
(13). 
Our findings suggest that the
polymyxin B–resistant strains have
emerged because of antimicrobial
selective pressure and dissemination
of clonal strains. Further epidemio-
logic studies are necessary to corre-
late the emergence of polymyxin-
resistant Acinetobacter spp. isolates to
the clinical response with polymyxin
B therapy. Since the emergence of
polymyxin B resistance may leave no
efficacious drugs for the treatment of
infections caused by multidrug-resist-
ant Acinetobacter spp. isolates, strict
infection control measures must be
adopted to avoid the emergence and
spread of such isolates. The low accu-
racy of routine susceptibility tests,
especially disk diffusion, may jeop-
ardize rapid implementation of such
measures. 
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Multidrug-Resistant
Shiga Toxin–
Producing
Escherichia coli
O118:H16 in Latin
America
To the Editor: We report the first
isolation of a multiple antimicrobial
drug–resistant strain of Shiga
toxin–producing Escherichia coli
(STEC) O118:H16 from cattle in
Latin America. The strain was
isolated during a study of fecal STEC
in 205 healthy and 139 diarrheic cattle
on 12 beef farms in the state of São
Paulo, Brazil, in February 2000; one
case of STEC was found in a 1-
month-old calf with diarrhea. This
bovine STEC O118:H16 strain
showed resistance to eight
antimicrobial substances; the
following resistance (R)-genes were
detected: ampicillin (blaTEM1-like),
kanamycin and neomycin (aphA1),
streptomycin (strA/B), sulphame-
toxazol (sul2), tetracyclin (tet[A]),
trimethoprim (no dfrA1, A5, A7, A12,
A14, or A17), and trimethoprim/
sulphamethoxazol. The STEC O118:
H16 strain from Brazil was found to
be similar for virulence genes (Shiga
toxin 1 [stx1], intimin beta 1 [eae β1],
and EHEC-hemolysin [E-hlyA]) and
for antimicrobial drug resistance to
STEC O118:H16 strains, which were
isolated in different countries of
Europe (1). Beginning in 1986, STEC
O118:H16 was identified as an
emerging pathogen for calves and
humans in Belgium and Germany
(2–4). Cattle and human STEC
O118:H16 isolates were similar in
virulence attributes and antimicrobial
drug resistance and belonged to a
distinct genetic clone (1). Trans-
mission of these pathogens from
cattle to humans on farms was
observed (5).
Beginning in 1996, STEC
O118:H16 has become important as
an emerging pathogen in humans and
has been associated with bloody
diarrhea and hemolytic uremic
syndrome (2). Analysis of the
antimicrobial resistance profiles
showed that >96% of the European
STEC O118:H16 strains showed
resistance to one or more anti-
microbial drugs in contrast to the 10%
to 15% drug-resistant strains that
were detected among STEC
belonging to other serotypes (1,6,7).
STEC O118:H16 showing multi-
resistance in up to eight different
antimicrobial drugs predominated
among younger isolates, indicating
that drug resistance genes have
accumulated over time in STEC
O118:H16 strains. The frequency of
antimicrobial drug resistance in STEC
and Stx-negative E. coli in humans
and animals was compared in a study
by Schroeder et al. (8). Among human
clinical E. coli isolates, antimicrobial
resistance was less frequently
observed in STEC than in Stx-
negative strains, whereas in cattle,
antibiotic-resistant strains were found
at similar frequencies in both groups
of E. coli. The relatively higher
frequency of antimicrobial-resistant
STEC in cattle was explained by the
use of antimicrobial drugs in cattle
production, whereas human infections
with STEC are generally not treated
with antibiotics (8). Cattle could thus
be an important source of new
emerging antibiotic-resistant STEC
strains such as O118:H16. 
The genetic basis of antimicrobial
resistance in STEC O118:H16 is
broad, including R-plasmids, inte-
grons, transposons, and chromo-
somally inherited drug-resistance
genes. Fluoroquinolone resistance has
also been acquired by some STEC
O118:H16 strains (1). The hetero-
genicity of antimicrobial drug–
resistance patterns, the increase of
multidrug-resistant strains over time
